果醇和银醇可以通过肠道微生物群-大脑轴调节来改善肝肥胖症
Rodrigo Soares da Silva1,2, Ingrid Prata Mendonça1,2, Igor Henrique Rodrigues de Paiva1,2
1Laboratory of Ultrastructure, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), Brazil.
International journal of food sciences and nutrition
|September 28, 2023
概括
两种益生菌,果醇糖 (FOS) 和银醇糖 (GOS),通过改善肠道微生物群,减少肝脏脂肪和炎症,减少了与代谢功能障碍相关的脂肪性肝病 (MALSD).
科学领域:
- 微生物学 微生物学
- 代谢障碍 代谢障碍 代谢障碍
- 胃肠病学 胃肠病学
背景情况:
- 肠道功能障碍与代谢功能障碍相关的脂肪性肝病 (MALSD) 严重程度有关.
- 益生菌可能调节肠道微生物群并影响代谢健康.
研究的目的:
- 在高脂肪饮食诱导的MALSD模型中,评估果酸 (FOS) 和银酸 (GOS) 对肝脏脂肪生成,炎症和肠道微生物群的影响.
- 研究涉及肠道微生物群-大脑轴信号传递的潜在机制.
主要方法:
- 在动物中高脂肪饮食诱导的MALSD模型.
- 使用FOS和GOS的管理.
- 分析肝脏基因表达,血清标记物,肠道微生物群组成和下丘脑信号.
主要成果:
- FOS和GOS显著降低了胰岛素抵抗,高血糖和脂质失调.
- 益生菌降低了肝脏脂原性标记物 (SREBP-1c,ACC,FAS) 和炎症通路 (p-NFκB-65,IL-6,TNF-α) 的作用.
- FOS和GOS增加了有益细菌 (Bacteroides acidifaciens,Bacteroides dorei) 和调节了下丘脑POMC/GPR43信号传递.
结论:
- 通过减少肝脏脂肪生成和炎症,FOS和GOS有效地减轻了MALSD.
- 这些益生菌改善了肠道微生物群的组成和功能,影响了肠道微生物群-大脑轴.
- FOS和GOS代表了管理MALSD的潜在治疗策略.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Irritable Bowel Syndrome I: Introduction
304
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
304
Overview of Carbohydrate Metabolism
1.1K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.1K
Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
237
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
237


